AI assistant
Pharnext — Regulatory Filings 2016
Nov 3, 2016
1594_iss_2016-11-03_d35e17c5-d327-4bc9-ae8a-bfaef0c07a76.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Pharnext to attend Jefferies 2016 London Healthcare Conference
Paris, November 3rd 2016 – Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceuticals company developing an advanced portfolio of products in the field of neurodegenerative diseases, announces today its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hotel in London, UK.
This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world: biotechnologies, pharmaceuticals, generics, medtechs and healthcare services. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 B2B and investor meetings.
CONTACTS :
| Pharnext | NewCap | Media Relations (Europe) | Media Relations (US) |
|---|---|---|---|
| Pierre Schwich | Relations Investisseurs | Alize RP | Russo Partners |
| Directeur Financier | Julie Coulot | Caroline Carmagnol | Tony Russo, Ph.D. |
| [email protected] | [email protected] | Margaux Pronost | Matt Middleman, M.D. |
| +33 (0)1 41 09 22 30 | +33 (0)1 44 71 20 40 | [email protected] | [email protected] |
| +33 (0)1 44 54 36 64 | +1 212-845-4272 |
ABOUT PHARNEXT
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPIE®. Pharnext identifies and develops synergetic combinations of drugs that are already being used for other diseases. These PLEOMEDICAMENT® are developed at new lower doses and repositioned into new indications. The PLEOMEDICAMENT® offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com.